NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Synnovation Therapeutics

Synnovation Therapeutics

Private
Wilmington, DelawareHealthcare & Life Scienceshttps://www.synnovationtx.com/

Last Round

Series A

Jan 24, 2024

Total Funding Raised

$147M

Momentum

Top 1%

of companies Caplight tracks

Company Overview

Synnovation Therapeutics is a biotechnology company that develops precision small molecule therapies for the treatment of cancer and immunological diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

precision oncologysmall molecule therapeuticsPARP1 inhibitorPI3Kα inhibitorbiotechdrug discoveryclinical-stage biotechsolid tumor treatmentdrug developmentclinical trialsbiopharmalicensing agreementasset salecancer drugoncology pipeline

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Synnovation Therapeutics Comparables

Compare Synnovation Therapeutics with similar companies based on industry and business-model similarity.

Synnovation Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Duke Street Bio
89%
1cBio, Inc.
87%
Idience Co., Ltd.
83%

Synnovation Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AJan 24, 2024
Series AMay 24, 2023
SeedNov 24, 2021

Key People

Founding team and executive leadership

Wenqing Yao

Founder And CEO

Founding Team

Synnovation Therapeutics Investors

Notable investors and investment history

Synnovation Therapeutics investors
InvestorRounds
Sirona CapitalSeries A
Cormorant Asset ManagementSeries A
Lilly Asia VenturesSeries A
Nextech InvestSeries A
Lilly Asia VenturesSeries A
Cormorant Asset ManagementSeries A
Third Rock VenturesSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 28, 2026

    Acquired Excellergy Inc. for $2 billion.

  • Mar 20, 2026

    Novartis acquired PI3Kα inhibitor program for $3 billion.

Synnovation Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Synnovation Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Synnovation Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersWilmington, Delaware
Employee Range49
Year Founded2021
Last FundingJan 24, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.